Ability Biologics, a Montreal, Canada-based cell targeting company, raised US $18M in Seed funding.
The round was led by Amplitude Ventures with participation from FTQ, Investissement Québec, Charles River Laboratories, Theodorus and Alexandria Venture Investments.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Giles Day, Ability Biologics is a cell targeting company. Its AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multi-specific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics. It is dedicated to developing antibody therapeutics for areas of great unmet need.
Commenting on the news, Giles Day said: “At Ability, our platform overlays multiple approaches in a single molecule, enhancing specificity and selectivity to develop potent therapeutics with broad therapeutic windows. To do so, our antibodies employ tried and tested IgG formats that enable easier manufacturing, storage and administration, avoiding complex formats that introduce multiple risks from manufacturing to immunogenicity.”
FinSMEs
18/06/2024